Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results
M. Hoogendoorn (Rotterdam, Netherlands), I. Corro Ramos (Rotterdam, Netherlands), M. Baldwin (Ingelheim, Germany), L. Luciani (Paris, France), C. Fabron (Bourg-la-Reine, France), B. Detournay (Bourg-la-Reine, France), M. Rutten-Van Mölken (Rotterdam, Netherlands)
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Hoogendoorn (Rotterdam, Netherlands), I. Corro Ramos (Rotterdam, Netherlands), M. Baldwin (Ingelheim, Germany), L. Luciani (Paris, France), C. Fabron (Bourg-la-Reine, France), B. Detournay (Bourg-la-Reine, France), M. Rutten-Van Mölken (Rotterdam, Netherlands). Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results. 3153
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009
LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Indacaterol once-daily provides superior efficacy to salmeterol: A 12-week trial Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Cost effectiveness of umeclidinium bromide 62.5µg plus ICS/LABA versus ICS/LABA in COPD Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017
Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011
Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Once-daily NVA237 improves lung function in COPD patients: Pooled results of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Economic evaluation of salmeterol/fluticasone combination versus budesonide plus formoterol in Spain Source: Eur Respir J 2001; 18: Suppl. 33, 49s Year: 2001
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Pooled analysis of the efficacy and safety from two non-interventional studies of fluticasone propionate/formoterol pMDI Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009